Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 25.46M | 16.79M | 4.05M | 3.27M | 1.57M |
Gross Profit | 12.90M | 6.66M | 1.11M | 2.83M | -570.00K |
EBITDA | -2.43M | -7.36M | -12.18M | -15.13M | -33.70M |
Net Income | -3.62M | -8.74M | -14.73M | -16.77M | -32.86M |
Balance Sheet | |||||
Total Assets | 20.12M | 21.97M | 17.62M | 22.30M | 30.16M |
Cash, Cash Equivalents and Short-Term Investments | 448.03K | 477.20K | 1.19M | 31.00K | 2.52M |
Total Debt | 109.23K | 1.80M | 3.21M | 1.66M | 1.94M |
Total Liabilities | 10.38M | 14.00M | 14.16M | 15.39M | 16.25M |
Stockholders Equity | 2.31M | -112.50K | -383.56K | 1.15M | 6.02M |
Cash Flow | |||||
Free Cash Flow | -2.95M | -1.96M | -7.50M | -12.45M | -15.43M |
Operating Cash Flow | -2.55M | -1.40M | -7.44M | -11.66M | -13.97M |
Investing Cash Flow | -402.57K | -3.05M | 810.24K | 760.83K | -2.71M |
Financing Cash Flow | 3.41M | 3.55M | 9.90M | 10.06M | 17.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $44.56M | ― | -24.12% | ― | 18.82% | -9328.57% | |
68 Neutral | $57.67M | 4.26 | 20.78% | ― | -15.44% | ― | |
56 Neutral | $29.22M | ― | -2.68% | ― | 29.78% | 68.83% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
51 Neutral | C$26.98M | ― | -16.22% | ― | 16.24% | 46.47% | |
50 Neutral | C$30.20M | ― | -203.40% | ― | 14.82% | 64.51% | |
44 Neutral | C$28.94M | ― | -31.24% | ― | 44.21% | 21.93% |
Avicanna Inc. has successfully closed a non-brokered private placement, raising $1,000,000 through the issuance of 4,000,000 units. The proceeds will be used for general working capital, administrative expenses, and further production and research efforts, potentially enhancing Avicanna’s operational capabilities and market position in the cannabinoid-based product industry.
Avicanna Inc. announced the successful election of all management’s nominees as directors at its Annual General Meeting. The company also secured the reappointment of its auditors, indicating stability and continuity in its operations. This development underscores Avicanna’s commitment to maintaining its strategic direction in the cannabinoid-based product market, potentially strengthening its position and reassuring stakeholders of its governance and operational consistency.
Avicanna Inc. has announced its sponsorship of a Phase II clinical study to evaluate the effectiveness of oral cannabis extracts for osteoarthritic pain. This multi-centre, blinded, randomized, placebo-controlled study, led by Dr. Hance Clarke at the University Health Network, aims to assess the feasibility of a larger trial. The study is funded by a Canadian Institutes of Health Research grant, with Avicanna providing its proprietary CBD and THC capsules. This initiative underscores Avicanna’s commitment to advancing cannabinoid-based therapeutics and could enhance its positioning in the medical cannabis industry.
Avicanna Inc. has reported its first profitable quarter in Q1 2025, marking a significant milestone driven by cost efficiencies and margin improvements. The company achieved a net income of $74,154 and comprehensive income of $876,092, with adjusted positive EBITDA of approximately $431,000. Despite a slight 2% decrease in revenue compared to Q1 2024, Avicanna expanded its Canadian portfolio and announced a collaboration with Aspeya to enhance medical cannabis access in Canada. This strategic focus positions Avicanna for further growth in Canadian operations, international expansion, and advancement of its R&D pipeline.